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Background: Neuroendocrine tumours (NET) frequently metastasize to the liver. NET liver metastasis
has been shown to respond to Yttrium-90 microspheres therapy. The aims of the present study were to
define factors that predict the response to radio-embolization in patients with NET liver metastases.
Methods: From January 2006 until March 2009, all patients with NET liver metastasis that received
radio-embolization using TheraSphere® (glass microspheres) were reviewed. The response was deter-
mined by a change in the percentage of necrosis (DN%) after the first radio-embolization based on the
modified RECIST criteria (mRECIST) criteria. The following confounding variables were measured: age,
gender, size of the lesions, liver involvement, World Health Organization (WHO) classification, the pres-
ence of extra-hepatic metastasis, octereotide treatment and previous operative [surgery and (RFA)] and
non-operative treatments (chemo-embolization and bland-embolization).
Results: In all, 25 patients were identified, with a median follow-up of 21.7 months. The median age was
64.6 years, 28% had extra-hepatic metastasis and 56% were WHO stage 2. Post-treatment, the mean
DN% was 48.4%. Previous surgical therapy was a significant predictor of the response with a response
rate of 66.7 DN% vs. 31.5 DN% (P = 0.02). Bilateral liver disease, a high percentage of liver involvement
and large metastatic lesions were inversely related to the degree of tumour response although did not
reach statistical significance.
Conclusion: Radio-embolization increased the necrosis of NET liver metastasis mainly in patients with
less bulky disease. This may imply that surgical therapy before radio-embolization would increase the
response rates.
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Background
Neuroendocrine tumours (NET), formerly categorized into car-
cinoids and pancreatic islet tumours, represent a heterogeneous
group of slow growing tumours that originate from the same cell
line and have the potential to secret hormones. Although com-
monly of a gastroenteropancreatic origin, they can originate from
any neuroendocrine cell in the body. The overall incidence rate is
reported to be 5.25 per 100 000 people.1 An increase in the inci-
dence of the disease is noted, which is partly attributed to the
rising awareness and improved diagnostic strategies.2,3
In spite of the improvements in the recognition and treatment
of primary NET over the past decades, distant metastasis at the
time of diagnosis is reported in 13% of cases.1,3 The most frequent
site of distant metastasis is the liver.1 In fact, NET metastases
represent 10% of all metastatic liver lesions.4 These metastaticThis manuscript was presented at the IHPBA 2010 meeting in Argentina.
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lesions will subsequently be responsible for the more alerting and
disabling symptoms. Those are caused by a pressure effect on
adjacent structures, liver parenchymal replacement and/or
carcinoid syndrome as a consequence of excess hormonal secre-
tion.5 Surgical therapy offers the best chance of curing
localized NET liver metastasis, with a 5-year survival rate of
approximately 75%.6–8 Unfortunately, in the majority of patients
the disease progresses beyond this therapeutic window, leading to
a 5-year survival rate of less than 20%.6–8
Patients with metastatic disease are treated based on the assess-
ment of symptoms, performance status, tumour differentiation,
burden of the disease and progression rate.3 Multiple treatment
modalities have been implied and studied with variable results.
These include: surgery, biotherapy, chemotherapy, chemo-
embolization and radio-embolization, also called selective inter-
nal radiation therapy (SIRT). The main goals of treatment are
relieving symptoms, improving the quality of life and, if possible,
prolonging survival. The relatively low disease incidence and the
diversity in its presentation, has led to the lack of well-conducted
randomized controlled trials comparing the efficacy of different
treatment options.
Radio-embolization using yttrium-90 (90Y) microspheres has
been proven to be effective in the treatment of NET liver
metastases.9–11 TheraSphere® is the material used to deliver the
90Y radio-embolization in our centre, which is a glass-based
microsphere. The 90Y radio-embolization is considered an
expensive and not readily available line of therapy that when
associated with a significant response may have a potential sur-
vival benefit.12 Hence the increasing needs to define factors that
predict a better response to this therapy. This will also help in
achieving the maximum benefit of the available treatment
modalities.
The aims of the present study were to define factors that
can predict a better response in patients receiving 90Y radio-
embolization as a treatment for NET liver metastases.
Method
From January 2006 until March 2009, a total of 25 patients were
identified using the McGill University Health Centre NET data-
base. These patients were diagnosed with NET liver metastasis and
received 90Y therapy using TheraSphere® in the course of their
management.
The ‘McGill University Health Centre NET tumour board’ dic-
tates all treatment plans for those patients. The board includes
members of Hepato-pancreato-biliary surgery, interventional
radiology, nuclear medicine and endo-medical oncology. The
overall strategy is based on an aggressive surgical approach with
the aim to remove most (if not all) of the tumour burden in
patients with limited disease. Other treatment modalities were
considered when operative techniques were not applicable. 90Y
radio-embolization was reserved for patients with advanced (mul-
tifocal) disease within the liver and those who progressed or had
disease recurrence after surgical therapy (Fig. 1). All patients with
well-differentiated tumours are on long-acting octeriotide treat-
ment.13 Patients with abnormal liver function [international nor-
malized ratio (INR) > 1.5 IU, bilirubin > 60 mmol/l], and those
who had previous external beam radiation were not offered the 90Y
treatment. Furthermore, two patients were offered the 90Y treat-
ment but did not receive it because of a hepatopulmonary shunt
(>20%) and hence, were excluded from the present study.
Before treatment, baseline imaging was performed which
consisted of a tri-phasic computed tomography (CT) of the chest
and abdomen and an octreotide scan. A 18fluoro-deoxyglucose
(a) (b)
Figure 1 Therasphere therapy after surgical intervention. (a) An abdominal computed tomography (CT) scan showing a previously-treated
neuroendocrine tumour (NET) metastatic lesion with radiofrequency ablation (RFA) in segment VII (white arrow) with no enhancement.
However, multiple enhancing metastatic nodules (black arrow) are present adjacent to the ablated segment. (b) CT scan images of the same
patient 3 months after 90Y therapy of the right lobe of the liver showing a complete response. The vascular enhancement has virtually
disappeared, but the lesions themselves are persistent
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positron emission tomography (FDG-PET) scan was done for
seven patients who were seen more recently. The aims of these
studies are to measure tumour size, the percentage of hepatic
involvement and the extent of extra-hepatic disease. Afterwards,
three planning studies were performed. These were a dedicated
arterial angiography, a shunt study and volume CT acquisition.
The goal of the angiogram was to identify and embolize any
potential sources of non-target embolization to intestinal organs,
such as a right gastric artery, or the gastro-duodenal. Any at risk
vessels were embolized in the same session. With the angiographic
catheter in place, the patient was transferred to the Nuclear Medi-
cine department for the shunt study. This consists of injecting
Technetium-99 m labelled macro-aggregated albumin (MAA)
particles into the hepatic artery and monitoring to determine the
fraction shunted to the lungs. Finally, a dedicated CT scan was
performed with a direct contrast injection in the hepatic artery to
identify the lobe or segment being treated and allow precise
volume measurements. The correct dosing of 90Y to be adminis-
tered was calculated using the standard formula described by the
supplier. The inputs for this are the volume of the targeted area of
the liver, including normal and tumour tissue, the target radiation
dose measured in gray (Gy) and the percentage of the shunt
fraction. As all of these patients had normal underlying liver func-
tion, the target does range was 140 to 150 Gy.14
After angiographic confirmation, the 90Y microspheres are
delivered via the target artery using a selective, lobar or
bi-segmental, approach depending on the location of the NET
metastases. The patients were monitored for a few hours after
therapy to ensure the absence of acute complications. Patients
were regularly followed up afterward. This consists of clinical
assessment, a liver function test, a CT scan and a nuclear scan at
3–4 weeks after the treatment and every 3–6 months thereafter.
During which, visualization of the treatment response and
observation for late complications is addressed. The treatment
response was assessed by measuring the percentile difference in
tumour necrosis (DN%) before and after the treatment rather
than the change in tumour diameter. This is done using the
modified RECIST criteria (mRECIST), which is the recom-
mended method in measuring the tumour response to embolic
therapies.15 According to this criterion, the response of target
lesions was classified into four categories. A response is said to
be ‘complete’ when the entire intra-tumoural arterial enhance-
ment disappears. A ‘partial response’ is defined as having at least
a 30% decrease in the sum diameter of the enhancing portion of
the target lesions in reference to the baseline sum of diameters.
A ‘progressive disease’ is an increase of at least 20% in the sum
of the target lesions in reference to the baseline. Any case that
does not qualify for either a partial response or progressive
disease is classified as ‘stable disease’.15
Descriptive statistics are presented in the form of medians and
percentages summarizing the following variables: age, gender,
size (<2, 2–4 and >4 cm), liver involvement (<33%, 33–66%
and >66%), WHO classification, the presence of extra-hepatic
metastasis, octereotide treatment and previous operative (surgery
and RFA) and non-operative treatments (chemo-embolization
and bland-embolization). Independent-samples t-test, the paired
t-test and Pearson’s correlation coefficient were used to study the
significance of a response. Analysis of covariance (ancova) was
used to adjust for possible confounders. Overall survival is pre-
sented using the Kaplan–Meier survival method. The objective is
to study the effect of these defined variables on the rate of the
tumour response (DN%) to 90Y treatment.
Results
A total of 25 patients were enrolled in the study (16 males and 9
females); summarized in Table 1. Their median age was 64.6 years
(range 34.6–90.4) and the median follow-up was 21.7 months
(range 3.9–44.2) starting when patients had their first radio-
embolization treatment. Most tumours are metastasis from a pan-
creatic primary (n = 13). Others originate from the small
intestines (n = 6), lungs (n = 2), colon (n = 1) and of an unknown
origin (n = 3). Diagnosis was based on the radiological appearance
and a confirmatory histopathological examination in all cases.
However, not all pathology reports had sufficient data to conclude
an accurate WHO staging (Table 1).
All patients had TNM stage IV metastatic NET to the liver. The
maximum diameter of the largest liver lesion was less than 2 cm in
four patients, between 2–4 cm in 14 patients and more than 4 cm
in seven patients. Lesions were confined to one liver lobe in eight
patients, while involving both lobes in 17 patients. Radiological
measurement of the tumour bulk was calculated against the total
liver volume by an expert radiologist and expressed as the per-
centage of liver involvement. Based on this, patients were stratified
into three categories; 11 patients had 33% or less involvement, five
patients had between 33% and 66% involvement and nine
patients had more than 66% liver involvement. Extra-hepatic
metastases were discovered in seven patients at the time of diag-
nosis. Pathology review revealed 13 patients (52%) with well-
differentiated NET (Table 2).
A total of 43 treatment sessions using 90Y radio-embolization
were performed. Eleven patients had a total of two sessions, two
patients had three sessions and one patient had four sessions. The
mean radiation dose per treatment was 141.1 Gy (range =
90–159). In general, treatment sessions were planned so that
patients received no more than one dose of 90Y in the target liver
volume. Two patients did undergo re-treatment in the same area
at an interval of about 1 year, these patients had responded ini-
tially, but then progressed. No patients received three or more
treatments in the same target volume. The average time interval
from diagnosis to the first 90Y was 53 months. The overall differ-
ence in necrosis observed after 90Y treatment is 48.4 DN% which is
highly significant (P < 0.001). Before radio-embolization, 20
patients (80%) were on octeriotide treatment, 12 patients (48%)
underwent a total of 16 operative treatments (eight liver resections
and eight radio-frequency ablations) and six patients (24%)
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underwent a total of seven non-operative treatments (five bland-
embolization and two arterial embolization).
Although no immediate complications were reported, seven
patients had grade 1–2 toxicities in the following 30 days. These
complications included mild abdominal pain, itching, generalized
fatigue, a low grade fever, weight loss and nausea and vomiting.
Two other patients suffered grade 3–4 toxicities. One patient had
abdominal pain that necessitated re-admission for pain control
and the other had evidence of portal vein thrombosis on radio-
logical studies. One patient died within 4 months as a result of a
bleeding perforated duodenal ulcer thought to be caused by
escaped beads. During the follow-up period, 12 out of the 25
patients died.
The mean DN% was 48.4% 38.7. Fifteen patients (63%) had
at minimum a partial response to therapy based on the mRECIST
criteria by having >30% DN%. Patients who had a previous opera-
tive intervention had a higher response rate of 66.7 DN% vs. 31.5
Table 1 Baseline characteristics
Patients details (total = 25)
Gender
Male (n) 9 (36%)
Female (n) 16 (64%)
Age (years) (median) 64.6 (56.9–69.12)









Stage 2 14 (56%)




Well differentiated 3 (12%)
Missing 8 (32%)
Extra-hepatic metastases n (percentage)
Yes 7 (28%)
No 18 (72%)




Liver lobes involved n (percentage)
Unilateral 8 (32%)
Bilateral 17 (68%)
Maximum diameter of liver lesions n (percentage)
<2 cm 5 (20%)
2–4 cm 10 (40%)
>4 cm 10 (40%)
Treatment details
Before yttrium treatment n (percentage)
Octeriotide 20 (80%)
Non-operative modalities d6 (24%)
Operative modalities 12 (48%)
Number of yttrium sessions n (percentage)
1 session 12 (48%)
2 sessions 10 (40%)
3 sessions 2 (8%)
4 sessions 1 (4%)
Table 2 A summary of tumour response rates (DN%)
Factor n Tumour response
rates (DN%)
Previous operative treatment (surgery
or radio-frequency ablation)
Yes 12 66.6 %
No 13 31.5 %
P-value = 0.02*
Liver lobes involved
Unilateral 9 66.3 %
Bilateral 16 40.0 %
P-value = 0.11
Extent of liver involvement
66% 16 53.2 %
>66% 9 40.0 %
P-value = 0.43
Maximum diameter of liver lesions
4 cm 15 52.0 %





Yes 6 51.7 %
No 197 47.7 %
P-value = 0.82
Octeriotide treatment
Yes 20 48.0 %
No 5 50.0 %
P-value = 0.92
*Statistical significance was retained after adjusting for possible con-
founders; namely, liver lobes involved, extent of liver involvement and
maximum diameter of liver lesions (P = 0.041).
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DN% (P = 0.02). Moreover, liver involvement of less than 66%,
unilateral liver involvement and smaller metastatic lesions tended
to have a higher response rate but this did not reach statistical
significance; Table 2. There was no apparent linear correlation
between radiation dose, per targeted liver volume, and the per-
centile difference in tumour necrosis (r = 0.16).
Patients who underwent surgical treatment tended to have uni-
lobar disease (58%), with no more than 66% of liver involvement
(83%) and a maximum tumour diameter of less than 4 cm (67%).
Although formal multivariant analysis was not performed due to
sample size limitation, analysis of covariance was attempted to
control for possible confounders. After adjusting for liver lobes
involved, the extent of liver involvement and the maximum
tumour diameter, previous operative intervention remained a sta-
tistically significant predictor of a higher response rate (P 0.041).
Discussion
The ‘silent’ nature of NET progression draws attention towards
exploring the best way to manage its spread. Around one in every
seven patients has apparent metastatic disease at the time of diag-
nosis.16 Moreover, 25–90% of patients are expected to develop
metastases during the course of the disease; the liver being mostly
involved.16 Multiple treatment options are currently available and
are constantly being explored with the aim for better outcomes.
Surgery has been known to be the best option for resectable
tumours. Unfortunately, NET liver metastasis are commonly mul-
tiple, small and scattered in nature.17,18 Other options such as
bland-embolization, chemo-embolization, somatostatin ana-
logues, systemic chemotherapy and radiotherapy have been used
with little to no survival benefit.19–22 The current management of
NET liver metastasis requires the use of these different treatments
interchangeably. One of the emerging treatment modalities is
radio-embolization using radioactive 90Y microspheres. It is a
modality that carries a promise of a safe and effective option as
proven by multiple trials.10,11
TheraSphere® is a material used to deliver the 90Y radio-
embolization. It consists of 90Y-embedded glass microspheres that
are pure b-emitters (high energy) with a half-life of 64.2 h. The
emitted radiation exhibits a mean tissue penetration of 2.5 mm
and a maximum of 11 mm. These microspheres deliver a high
dose of radiation to the intended malignant cells. There is a
minimal ischaemic effect on the normal liver tissue, as the size and
number of infused particles and the hypervascular nature of NET
liver metastasis. Therefore, associated toxicities are more tolerable
when compared with other embolic-based treatment options.23–25
On the other hand, it has its share of drawbacks. Planning a
radio-embolization consumes a lot of hospital resources; CT
scans, angiographic liver mapping and +/- shunt embolization are
of the minimal basic requirements. Furthermore, the micro-
spheres are expensive and require an experienced interventional
radiologist to perform the treatment. Hence, identifying the pre-
dictors of a response is an important step towards maximizing the
benefit of 90Y radio-embolization use.
In concordance with recent studies, our data shows a better
response to 90Y radio-embolization treatment in patients with less
bulky NET liver metastasis. An aggressive surgical approach to
debulk the tumour showed a significant improvement in response
rates. In addition, the tumour burden (measured by percentage of
liver involvement, the diameter of the lesions and the spread to
both liver lobes) was inversely related to the amount of tumour
necrosis in response to 90Y treatment. These results suggest that
debulking procedures, such as surgery and RFA, have an essential
role in reducing the tumour burden, allowing the 90Y treatment to
achieve higher response rates.
A phase II trial by Sexena A et al. also looked at factors predict-
ing response and survival after 90Y radio-embolization for unre-
sectable NET liver metastases.26 Although measurement of the
response was based on a change in actual tumour diameter rather
than necrosis, three factors associated with a better response were
identified. Those were female gender, a well-differentiated tumour
and low hepatic tumour burden, in addition a longer survival was
seen in patients with a better response.26 Our data validates further
the importance of tumour burden as a predictor of response to 90Y
radio-embolization treatment. A tumour involving more than
66% of the liver had a response rate of 40 DN% vs. 53.1 DN% in
patients with less than 66% involvement. Bilobar disease was asso-
ciated with a lower response (39.4 DN%) vs. unilobar disease (64.4
DN%). It is noted that previous surgical debulking was not asso-
ciated with a better response to the treatment in the previous
study by Sexena et al. In comparison, the present study shows a
statistically significant higher response rate; 66.7 DN% vs. 31.5
DN% (P 0.02) in patients who had prior surgical treatment. Other
studies, however, demonstrated the beneficial rule of surgical
intervention in patients with metastatic NET to the liver.16,27 Their
data have suggested a better survival in patients undergoing an
early surgical reduction of tumour load. Also, curative surgical
intent showed better survival outcomes compared with palliative
intent.
Several studies have looked at possible outcome predictors in
patients with metastatic NET, verifying the prognostic values of
TNM staging system as well as the WHO classification.28–31 Other
variables have also been identified as potential confounders. Most
of these are related to the tumor’s biology, bulk and extent of
spread.31,32 A review of 118 patients by Cosimo D et al. suggested
that young age, a low number of liver metastasis, surgical treat-
ment of primary and metastatic disease, as well as a slow tumour
progression slope to be favourable prognostic factors.33 The
present study was not intended to examine the effect of 90Y treat-
ment on survival. Nevertheless, the overall median survival from
the time of 90Y treatment was 35.27 months which is slightly
higher than previously published studies (Fig. 2).12 In respect to
the small number of patients studied in this review, no significant
difference in survival could be attributed to any of the favourable
predictors.
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The expanding literature is in support of the use of cytoreduc-
tive strategies in patients with metastatic NET in terms of
symptom control and overall survival.16,22,26,33–35 Detecting survival
advantage in patients with advanced NET disease that would
require 90Y treatment is not easy to conduct. The complexity and
the heterogeneity of the patients in addition to the rarity of the
disease are the main reasons. The present study, however, is
focused to determine factors predicting the tumour response to
90Y treatment. We believe that a collaborative multi-centric, ran-
domized trial is needed to clarify the benefits of the cytoreductive
strategies when combined with 90Y treatment.
Conclusion
Radio-embolization increased the necrosis of NET liver metasta-
sis. The benefit is greater in patients with less bulky disease. This
implies that surgical treatment (resection or RFA) before radio-
embolization would allow 90Y treatment to achieve higher rates of
response. The noted difference in the percentage of tumour necro-
sis was doubled in patients who had surgical treatment before the
90Y radio-embolization. This effect might be attributed to the
differences in the total radiation delivered to the smaller
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